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Abstract 
Recent studies show that more than one-third of U.S. adults (over 72 million 
people) were obese in 2005–2006. This includes 33.3% of men and 35.3% of women. 
Obesity is a primary factor in the development of metabolic syndrome, a condition that 
places individuals at high absolute risk of mortality and morbidity. The use of a 
nutritionally balanced diet aimed at weight reduction has the potential to decrease the 
prevalence of obesity, therefore reducing the incidence of metabolic syndrome and its 
consequences.  
The purpose of this project was to investigate whether individual nutrition 
counseling would improve the outcomes of patients with metabolic syndrome. A trans-
disciplinary team of faculty and graduate students from nutrition and nursing served as 
consultants and educators at a clinic for the uninsured in a southeastern city in the United 
States. This study was a one-group before-and-after design, with baseline data obtained 
on patients prior to the practice change. The study ran for six months. The intervention 
was an evidence-based practice change incorporating intensive dietary program for 19 
patients with metabolic syndrome and an evaluation of the effect of that change on 
lipoproteins, glucose, blood pressure, weight, and waist circumference. 
Although there were no positive changes in weight or waist circumference, the 
participants did enjoy a significant decrease in blood pressure, fasting glucose and plasma 
lipids. None of these changes were significantly associated with the dietary intervention.  
Based on the most current evidence, the most effective way to reduce risks associated 
with metabolic syndrome is weight reduction, adequate nutrition, and exercise.  
 
 
Chapter One: Introduction 
Cardiovascular disease is a major cause of morbidity and mortality in the U.S. 
(Rosamond, 2007) and prevention, and treatment has been at the center of scientific 
research for many years. As risk factors for cardiovascular disease were identified, it 
became clear that more than one risk factor tended to occur in individuals. Obesity, type 
2 diabetes, dyslipidemia, and hypertension are often present in individuals with 
cardiovascular disease. This cluster of risk factors became known as “syndrome X,” 
“insulin resistance syndrome,” and, the most widely and currently accepted term, 
“metabolic syndrome” (Reaven, 1988).   
In 1997, the World Health Organization (WHO) published a landmark document 
recognizing obesity as a worldwide disease that poses a serious threat to public health 
(Mokdad et al., 1999). Persons who are overweight or obese have a substantially 
increased risk for morbidity from numerous chronic disorders, such as diabetes, 
hypertension and cardiovascular disease. “Adults aged 40–59 had the highest obesity 
prevalence compared with other age groups. Approximately 40 percent of men in this age 
group were obese, compared with 28 percent of men aged 20–39, and 32 percent of men 
aged 60 and older. Among women, 41 percent of those aged 40–59 were obese compared 
with 30.5 percent of women aged 20–39” (Ogden, Carroll, McDowell, & Flegal, 2007, p. 2).  
The latest data from the Centers’ for Disease Control (CDC) (2008) indicate that nearly 
36% of black Americans, about 29% of Hispanics, and 24% of whites are obese. 
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According to the National Cholesterol Education Program (NCEP) panel, metabolic 
syndrome will soon have a greater impact on premature coronary artery disease than 
tobacco (Third Report, 2001). However, traditional risk factors, including metabolic 
syndrome, cannot explain the greater health burden of disease seen in obese African 
Americans. Thus, it is imperative to identify additional risk factors that may contribute to 
disease development or identify early indication of disease and examine the effect of 
lifestyle and dietary management programs on these risk factors. 
Metabolic syndrome is a grouping of risk factors that, when three or more are 
present, increase a person’s risk for developing diabetes and heart disease. These risk 
factors include insulin resistance, obesity, hyperlipidemia, hyperglycemia, and 
hypertension (Grundy, Brewer, Cleeman, Smith & Lenfant, 2004). However, further 
examination of the criteria by which the metabolic syndrome is diagnosed revealed that 
these criteria differ depending on who established them (Grundy et al., 2005). 
In 1998, the World Health Organization (WHO) developed a consensus definition 
of metabolic syndrome. This was followed by definitions by the European Group for the 
Study of Insulin Resistance (EGIR) in 1999, the third Adult Treatment Panel of the 
National Cholesterol Education Program (NCEP-ATP III) in 2001 and the American 
Association of Clinical Endocrinologists (ACCE) in 2003.  
The International Diabetes Federation (IDF), in a global consensus statement, 
presented a new, clinically accessible definition of the metabolic syndrome, representing 
the views of experts in the fields of diabetes, cardiology, lipidology, public health, 
epidemiology, genetics, metabolism, and nutrition from six continents (Grundy, Brewer 
et al. (2004).  According to the IDF 2005 definition, for a person to be defined as having 
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the metabolic syndrome the person must have central obesity (defined as waist 
circumference ≥ 94 cm for men and ≥ 80 cm for women) plus any two other risk factors. 
The NCEP-ATP III definition from 2001 was revised in 2005 and is based on any three 
risk factors. Similarly, the American Heart Association (AHA) and the National Heart, 
Lung, and Blood Institute (NHLBI) base their definition on the presence of three risk 
factors. Table 1.1 presents the evolution of the various definitions.  
Evidence-based obesity treatment and medical nutrition therapy for obesity 
related chronic diseases such as metabolic syndrome includes individualized counseling. 
This is designed to increase knowledge and skills to improve adherence to healthy 
behaviors including the adoption of a diet rich in whole grains, fruits and vegetables, and 
a physically active lifestyle (Emili, Abushomar, & Nair, 2007).  
The Extent of the Problem 
It is difficult to determine the prevalence of metabolic syndrome worldwide 
because of the differing criteria used to identify the condition (Ford, 2004). The IDF 
suggests that the data presented from the third National Health and Nutrition Examination 
Survey (NHANES III) surveys are a good estimation of the worldwide prevalence (IDF, 
2007). Findings from NHANES III suggest that 24% of American men and 23% of 
American women, or about 47 million people, have metabolic syndrome (see Table 1.2). 
These data were compiled in 2002, but recent statistics may be even higher. It has been 
reported that the prevalence of metabolic syndrome increases with age and its prevalence 
among Americans over the age of 60 is 42–43.5%. Mexican Americans were found to 
have the highest prevalence of metabolic syndrome at 31.9%. White Americans and 
African Americans had the lowest prevalence at 23.8% and 21.6%, respectively.
 
Table 1.1 Criteria Proposed for Clinical Diagnosis of Metabolic Syndrome 
Clinical measure WHO (1998) EGIR (1999) ATP III (2001) AACE (2003) ATP III (2004) IDF (2005) AHA/NHLBI 
(2005) 
Insulin resistance IGT, IFG, 
T2DM, or 
lowered insulin 
sensitivity plus 
any two of the 
following:  
Plasma insulin > 
75th percentile 
plus any two of 
the following: 
None, but any 
three of the 
following five 
features: 
IGT or IFG plus 
any of the 
following based 
on clinical 
judgment: 
None, but any 
three of the 
following five 
features: 
None None, but any 
three of 
following five 
features: 
Body weight Men waist to hip 
ratio > 0.90 
Women waist to 
hip ratio > 0.85, 
or BMI > 30 
kg/m2 
Waist 
circumference 
(WC) ≥ 94 cm 
WC  
Men ≥ 102 cm 
Women ≥ 88 cm 
BMI ≥ 25 kg/m2 WC  
Men ≥ 102 cm 
Women ≥ 88 cm 
Increased WC  
Men > 94 cm 
Women > 80 cm 
plus any two of 
the following: 
WC  
Men ≥ 102 cm 
Women ≥ 88 cm 
Lipids TG ≥ 1.7 
mmol/L and/or 
HDL-C < 0.91 
mmol/L 
TG ≥ 2.0 
mmol/L and/or 
HDL-C <1.01 
mmol/L or 
treated for 
dyslipidemia 
TG ≥ 1.69 
mmol/L, HDL-C 
< 1.03 mmol/L 
TG ≥ 1.69 
mmol/L and 
HDL-C < 1.03 
mmol/L 
TG ≥ 1.69 
mmol/L, HDL-C 
< 1.03 mmol/L 
TG ≥ 1.7 
mmol/L or on 
TG Rx, HDL-C 
< 1.03 mmol/L 
or on HDL-C Rx 
TG ≥ 1.69 
mmol/L or on 
TG Rx, HDL-C 
< 1.03 mmol/L 
or on HDL-C Rx 
BP ≥ 160/90 mm Hg ≥ 140/90 mm Hg 
or on 
hypertension Rx 
≥ 130/85 mm Hg ≥ 130/85 mm Hg ≥ 130/85 mm Hg ≥ 130 mm Hg 
systolic or ≥ 85 
mm Hg diastolic 
or on 
hypertension Rx 
≥ 130 mm Hg 
systolic or ≥ 85 
mm Hg diastolic 
or on 
hypertension Rx 
Glucose IGT, IFG, or 
T2DM 
IGT or IFG (but 
not diabetes) 
> 6.11 mmol/L 
(includes 
diabetes) 
IGT or IFG (but 
not diabetes) 
> 5.6 mmol/L 
(includes 
diabetes) 
≥ 5.6 mmol/L 
(includes 
diabetes) 
≥ 5.6 mmol/L or 
on hypoglycemic 
Other mALB > 30 mg 
creatinine 4 
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African American and Mexican American women had a greater prevalence of metabolic 
syndrome than the men of the same ethnicity (Gami et al., 2007). 
Currently there are no data for the prevalence of metabolic syndrome in the state 
of Florida or Duval County. According to self-reported Behavioral Risk Factor 
Surveillance System (BRFSS) data, 55.8% of Florida adults are overweight or obese, 
which approximates to 7 million residents (Florida Department of Health [DOH], 2001). 
Of these, 18.8% or nearly 2.5 million people are obese, with a body mass index (BMI) ≥ 
30. The 2001 BRFSS survey reported that the prevalence of being overweight among 
adult men and women in Florida has increased by 58% since 1986, and the prevalence of 
obesity has increased by 93% since 1986 (CDC, 2002) .  
Treatment 
The primary goal of clinical management of metabolic syndrome is to reduce risk 
for clinical atherosclerotic disease. Weight reduction and increased physical activity are 
first-line therapies for metabolic syndrome. Drug therapy is recommended when low-
density lipoprotein cholesterol (LDL-C) is not lowered sufficiently by lifestyle 
modifications.  
Purpose 
The purpose of this project was to investigate whether an intensive dietary 
program including individual nutrition counseling would improve the outcomes of 
patients with metabolic syndrome in an uninsured population.  
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Definition of Terms  
Metabolic syndrome. For the purposes of this study, the NCEP-ATP III (2002) 
criteria will be used (see Table 1.3).  
 
 
Intensive dietary program. The individualized diet program will be based on the 
Therapeutic Lifestyle Changes (TLC) diet.  It is targeted to people whose LDL 
cholesterol is above the goal level for their category of risk for heart disease. These are 
the essential components of TLC diet (see Table 1.4).
Table Deleted
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Dietary intake was assessed using the single 24-hour recall method by graduate 
nutrition interns. Before testing, all subjects were instructed to maintain their usual 
dietary habits. In this study, the daily energy intake and percentages of the ADA food 
pyramid groups. 
Table Deleted
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Chapter Two: Literature Review 
This chapter presents an overview of the search strategies used for identification 
and retrieval of the evidence. This is followed by a brief overview of cardiovascular 
disease and a review of the evidence with respect to the effects of metabolic syndrome on 
cardiovascular disease. A discussion of the relationship between socioeconomic position 
and metabolic syndrome is followed by a synthesis of the evidence for the use of the 
Mediterranean and TLC diet. Evidence for non-pharmacologic measures for the treatment 
of metabolic syndrome is also addressed.  
Search Strategies 
For this review, the following databases were searched: The Cochrane Library, 
(inception to March, 2008), MEDLINE (inception to March, 2008), OVID (inception to 
April, 2008), CINAHL (March, 2008), and MD Consult (inception to April, 2008). There 
were no language restrictions for either searching or trial inclusion. The search strategy 
below was used and adapted to suit the individual databases. Specific journals cited most 
frequently included Annals of Internal Medicine, Circulation, Heart, Diabetic Medicine, 
and The Journal of the American Dietetic Association. Keywords used included: 
metabolic syndrome, obesity, and dietary factors. Searches were limited to randomized, 
controlled trials (RCT) and meta-analyses conducted with human subjects investigating 
the treatment of metabolic syndrome. In addition, a manual search of citations from 
relevant original studies and review articles was performed. The final search produced 
one recent Cochrane Review, three recent meta-analyses, one Agency for Healthcare 
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Research and Quality (AHRQ) guideline and six randomized controlled trials (RCTs).  
The search was then updated through examining references from meta-analyses and 
review articles. 
Metabolic Syndrome and Cardiovascular Disease 
 According to the AHA, (2007), more than 1 million Americans would suffer a 
first or recurrent coronary event and nearly 500,000 of these would result in death. 
Cardiovascular disease is the leading cause of death for both men and women, and its 
prevalence increases with age. Despite known lifestyle changes and risk-factor 
modification with pharmacologic and non-pharmacologic therapies, many patients are 
still at risk for a cardiac occurrence.  
There is strong evidence to suggest that metabolic syndrome doubles the risk for 
cardiovascular disease and raises the risk for diabetes and mortality fivefold over a 5- to 
10-year period (Greenstone, 2008). The data supporting this relationship are outlined in 
Table 2.1.  
 Data from NHANES III (2006) were used to examine the frequency and 
clustering of the risk factors that make up the metabolic syndrome. From the 12,332 
subjects aged 30–74 years in the NHANES sample, this study identified 1,513 who were 
free of diabetes and met the definition of the metabolic syndrome. When compared to the 
U.S. population, this represents a sample of 16.5 million persons with metabolic 
syndrome. This study demonstrated that the most common components of the metabolic 
syndrome (present in more than 75% of subjects) were increased waist circumference (> 
40 inches in men and > 35 inches in women), high BP (≥ 130/85 mm Hg), high  
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triglycerides (≥ 150 mg/dL), and low HDL-C (≤ 40 mg/dL in men and ≤ 50 mg/dL in 
women). Impaired fasting glucose (≥ 110 mg/dL), the least common risk factor, was 
evident in 22% of men and 17% of women (Grundy et al., 2005).  
Gami et al. (2007) performed a meta-analysis of longitudinal studies that assessed 
any cardiovascular event outcomes or mortality in people with three or more coronary 
risk factors (regardless of whether this was termed the metabolic syndrome) compared 
with people without the diagnosis of metabolic syndrome. A total of 37 cohort studies 
from 1971 to 1997 including 172,573 individuals were included. This meta-analysis 
showed patients with metabolic syndrome had a relative risk (RR) of cardiovascular 
events and death of 1.78 (95% confidence interval [CI] 1.58, 2.00). The association was 
stronger in women (RR 2.63 vs. 1.98, p = 0.09), in studies enrolling lower risk 
individuals (RR 1.96vs. 1.43, p = 0.04), and in studies using the WHO definition (RR 
2.68 and 2.06 vs. 1.67 for National Cholesterol Education Program definition and 1.35 
for other definitions; p = 0.005). The association remained after adjusting for traditional 
cardiovascular risk factors (RR 1.54, 95% CI, 1.32, 1.79). The population of patients in 
this trial was probably heterogeneous in that the review included studies of overweight 
patients aged over 18 years. There was little description of the patients in the individual 
studies.  
Gami et al. (2007) found that (a) definitions of metabolic syndrome based on 
factor analysis were far more predictive of cardiovascular events and death than were 
other definitions; (b) the WHO-based criteria were better than NCEP-based criteria in 
predicting cardiovascular events and death; and (c) the substitution of BMI for waist 
circumference or waist-to-hip ratio in these criteria did not appear to affect their 
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outcomes.   Inclusion and reporting biases in the RCTs may have limited the assessment 
of the efficacy of lowering LDL concentration in diabetic patients without coronary heart 
disease. Most trials of lipid lowering interventions for primary prevention of coronary 
heart disease excluded diabetic patients by varied and ambiguous criteria. 
A meta-analysis by Galassi, Reynolds, and He (2006) included a total of 21 
prospective cohort studies. Among the 21 studies, 11 were conducted in the U.S. and 10 
in Europe. The number of subjects ranged from 318 to 19,223. The ATP III criteria were 
used in 16 studies, and the WHO criteria were used in 5. Two studies used both criteria. 
The RR of cardiovascular disease associated with the metabolic syndrome in each study 
and overall is > 1.0 and all but five were statistically significant. Individuals with the 
metabolic syndrome had an overall RR of cardiovascular disease of 1.61 (95% CI, 1.42, 
1.83) compared with individuals without the metabolic syndrome, Prevalence of the 
metabolic syndrome varied from 8.8% to 92.3%. However, the highest prevalence of the 
metabolic syndrome (75.6–92.3%) was observed in the three studies in which all study 
participants had type 2 Diabetes.  
A significant increase in the risk of cardiovascular disease associated with the 
metabolic syndrome was found when data were analyzed according to sex, length of 
follow-up, study country, and history of cardiovascular disease at baseline (Galassi et al., 
2006).   The RR was higher among women compared with men and those studies with 
follow-up that was longer than five years. Compared with the overall analysis, the RR 
was slightly reduced in studies that were conducted on non diabetic patients. The meta-
analysis indicated that individuals with metabolic syndrome have a 61% increased risk of 
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cardiovascular disease compared with individuals without the metabolic syndrome 
(Galassi et al., 2006).  
Many experts believe that early and efficient identification of patients with 
metabolic syndrome is important and that it is essential to use more advanced short-term 
risk assessments such as those used in the Framingham Study. Grundy et al. (2005) 
clearly states that these are the tools that should be used for short-term risk assessment. 
The Framingham Risk Score (FRS) was derived from the Framingham Heart Study, and 
is the most commonly recommended tool in the U.S. for global risk assessment in the 
primary prevention setting (Ingelsson et al., 2007). Short-term absolute risk, defined as 
the probability of a person developing a hard CHD endpoint (myocardial infarction or 
cardiac death) in the next 10 years, can be estimated by calculating the number of 
Framingham points assigned to each graded risk (see Table 2.2). At least three recent 
studies have compared the short-term predictive value of the metabolic syndrome criteria 
with that of the FRS (Obunai, Jani & Dangas, 2007).  
There is evidence to suggest that abdominal obesity is an independent risk factor 
for the development of diabetes, hypertension, hyperlipidemia and cardiovascular disease 
in individuals with BMI < 35 (Carr & Brunzell, 2004). Abdominal obesity is also 
associated with the metabolic syndrome.  Measurement of waist circumference is the 
simplest clinical method to detect abdominal obesity.  
Katzmarzyk, Janssen, Ross, Church & Blair (2006) compared the predictive 
ability of the NCEP-R and IDF metabolic syndrome criteria for mortality risk, and 
examined the effects of waist circumference on mortality within the context of these 
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criteria. Their sample included 20,789 White, non-Hispanic men aged 20–83 from the 
Aerobics Center Longitudinal Study. “The study concluded that waist circumference is a 
valuable component of metabolic syndrome. However, the change in the IDF definition 
of metabolic syndrome of an elevated waist circumference warrants caution given that a 
large proportion of men with normal waist circumference have multiple risk factors and 
an increased risk of mortality” (p. 406). 
General Treatment Strategies for Metabolic Syndrome 
The primary goal of clinical management of metabolic syndrome is to reduce risk 
for clinical atherosclerotic disease. The NCEP guidelines recommend a two-pronged 
approach to clinical management of the metabolic syndrome: (a) reversing underlying 
lifestyle causes, such as obesity, atherogenic diet, and physical inactivity; and (b) treating 
associated non-lipid and lipid risk factors (NCEP Expert Panel, 2002). Weight reduction 
and increased physical activity are first-line therapies for metabolic syndrome.   Obesity, 
hypertension, hyperlipidemia and type 2 Diabetes may mask underlying metabolic 
syndrome, which is characterized by atherogenic dyslipidemia, elevated blood pressure, 
insulin resistance, proinflammatory cytokines and a prothrombotic state. Treatment of the 
metabolic syndrome involves appropriate risk assessment for potential future cardiac 
events. The use of the Framingham risk assessment tool is helpful in predicting 10-year 
risk of coronary heart disease and stratifying patients as to their need for intensive 
treatment (Ingelsson, et al., 2007). According to the NCEP, measurements of adiposity 
and lipid levels are reliable identifiers for those with insulin resistance, and they describe 
what another group has termed “hypertriglyceridemic waist,” or a combination of 
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elevated measurements of waist circumference and triglycerides that is associated with 
increased cardiovascular risk (Tankó, Bagger, & Qin, 2005). 
Metabolic syndrome has been linked to insulin resistance, abdominal obesity and 
an unhealthy lifestyle. It has been estimated that if left untreated, those with metabolic 
syndrome will experience complications such as insulin resistance and atherosclerosis 
within 15 years, which presents time for intervention. Treatment of early symptoms may 
help to alleviate poor health outcomes and perhaps lessen the burden on health care costs. 
The most common treatments for metabolic syndrome are therapeutic lifestyle changes 
(TLC) (i.e. diet and exercise), weight loss, and medication (Grundy et al., 2005).  
Individuals with hyperlipidemia require initiation of therapeutic lifestyle changes 
including weight reduction, reductions in saturated fat and cholesterol in the diet, 
increased intake of soluble fiber (10–25 g/day) and plant stanols/sterols (2 g/day) and 
increased physical activity. First-line treatment for obesity is behavior modification, 
including a low-calorie, low-fat diet with calorie reduction of 500–1000 kcal/day, 
increased activity to 30 minutes per day most days of the week and behavioral counseling 
to improve stimulus control, reward positive lifestyle changes, and provide social 
support. 
Pharmacologic therapy for obesity is warranted after an adequate trial of 
behavioral modifications including diet, exercise, and behavioral therapy have failed to 
yield appropriate weight loss goals (Levy, Finch, Crowell, Talley, & Jeffery, 2007). Both 
orlistat and sibutramine are effective in inducing modest weight losses in conjunction 
with behavioral therapies. Surgical procedures for obesity may be considered for 
individuals with a BMI ≥ 40 who have obesity-related co-morbid conditions such as 
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hypertension, impaired glucose tolerance, diabetes, hyperlipidemia or obstructive sleep 
apnea, and where other options for weight loss have failed (Orchard et al., 2005). 
 Cholesterol management is a cornerstone of therapy for patients at risk for heart-
related events, with the focus of interventions aimed at reducing LDL-C concentrations. 
The reduction of LDL-C has been proven to have a significant impact in reducing the 
morbidity and mortality associated with cardiac disease. In addition to LDL-C reduction, 
results from the Framingham Heart Study and other trials have demonstrated that event 
risk is also independently associated with varying concentrations of HDL-C (Obunai et 
al., 2007).  With this in mind, the initial treatment protocol for cardiovascular disease 
centers on TLC, guidelines that prompt the patient to assess and modify eating and 
exercise habits. The goal of treatment is to reach and maintain ideal body weight, bring 
blood pressure to within normal limits, and reduce the impact that lifestyle choices have 
on total and LDL-C (Emili et al., 2007). 
Pharmacologic Measures for Treatment of Metabolic Syndrome.  Drug therapy, 
typically a statin, is recommended when low-density lipoprotein cholesterol (LDL-C) is 
not lowered sufficiently by lifestyle modifications. Treating non-lipid risk factors 
includes treating hypertension and using aspirin to reduce the prothrombotic state in 
patients with chronic heart disease (CHD). Insulin resistance, which is usually indicated 
by an impaired fasting glucose, is best improved by weight loss, a heart-healthy diet, and 
regular physical activity (Grundy et al., 2005).  
The ATP III (2005) recommends medication therapy for LDL levels > 160 
mg/dL, and patients at moderately high risk may consider a treatment goal of LDL < 100 
mg/dL. Statins are usually first-line treatment for hyperlipidemia, although individuals 
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with metabolic syndrome frequently have low high-density lipoprotein cholesterol (HDL-
C) and hypertriglyceridemia that may require additional medication with niacin or 
fibrates if statin therapy is unable to reduce their lipoprotein profile adequately. 
Nonpharmacologic Measures for Treatment of Metabolic Syndrome. Lifestyle 
intervention, inducing a modest BMI and waist reduction, can substantially affect the 
prevalence of metabolic syndrome and its components (Bo et al., 2007). Lifestyle 
modification is a primary treatment modality for all of the parameters that make up 
metabolic syndrome. Such modifications include changes in both dietary and exercise 
behaviors. These lifestyle interventions appear to be most effective in reducing waist 
circumference and blood pressure with relatively little effect on HDL-C and lipid 
abnormalities (Katzmarzyk et al., 2006).  The Diabetes Prevention Program (DPP) 
showed that intensive lifestyle changes resulting in losing 5–7% of weight through 
increased physical activity and a reduced calorie diet prevented or delayed the onset of 
type 2 diabetes by 58% in people at high risk for the disease. The DPP also showed that 
metformin, an oral diabetes drug, reduced the onset of type 2 diabetes by 31% (Diabetes 
Prevention Program Research Group [DPPRG], 2002).  
 Therapeutic Lifestyle Changes (TLC) Diet. Originally outlined in the American 
Heart Association’s Step 1 and Step 2 diets (Lichtenstein et al., 2002), the TLC diet 
consolidates the key elements into one set of guidelines. The primary diet message has 
remained basically unchanged over several decades: choose a diet rich in fruits, 
vegetables, whole grains, poultry, fish, and non-fat dairy foods, and limit intake of red 
meat, full-fat dairy foods and other high-fat animal products. The updated guidelines 
expand on what types and how much fat should be included in a “heart healthy” diet and 
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propose adding fiber and plant sterols to the diet as additional cholesterol-lowering 
strategies. “Thus, a comprehensive strategy to decrease cardiovascular morbidity and 
mortality should include primarily a cardioprotective diet” (de Lorgeri, M. et al, 1999, p. 
785). It should also be associated with other means aimed at reducing modifiable risk 
factors.   
Nutrition that leads to at least a 7–10% decrease in weight or BMI of hopefully < 
25 kg/m2, which includes at least five servings of fruits and vegetables daily, and has a 
negative energy balance on average of 500 calories per day is sufficient to have a 
significant impact on the components of the syndrome and the prevention of development 
of diabetes (DPPRG, 2002). TLC diet guidelines limit the intake of saturated fat (found in 
animal fats and tropical oils) and trans fat (hydrogenated or hardened), vegetable fat 
found in margarine and many types of cookies, crackers, and other snack foods. Both 
types of fat have been shown to raise LDL-C. On the other hand, liquid or soft 
polyunsaturated fats (vegetable oil, soft margarine) and monounsaturated fats are 
associated with lower LDL-C levels. The most common sources of monounsaturated fats 
in the U.S. diet are olive oil, canola oil, and nuts. In addition, the TLC guidelines advise 
consumers to consider using a stanol- or sterol-containing spread to further lower LDL-C. 
Patients are also advised to increase their intake of soluble fiber, either from supplements 
such as Metamucil or fiber-rich foods like oatmeal, beans, and apples (Lichtenstein et al., 
2002) (see Table 2.3).  
Mediterranean diet: Inspired by the low incidence of cardiovascular disease in 
Mediterranean countries, proponents of the Mediterranean diet recommend high intakes  
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of unsaturated fats (olive oil, nuts, fatty fish), fruits, vegetables, legumes, and whole 
grains (Estruch et al., 2006).  
Dairy products, eggs, poultry, and fish are eaten a few times per week, while red 
meat and sweets are eaten sparingly. Many small studies suggest the Mediterranean diet 
can reduce both cardiovascular risk and overall mortality. A 2005 cohort study of more 
than 74,000 healthy Europeans over 60 years of age revealed that those eating a 
Mediterranean-style diet had a significantly longer life expectancy than those following 
other dietary patterns. A three-month trial comparing two versions of the Mediterranean 
diet (one with olive oil, the other with nuts) with a low-fat AHA diet reported reductions 
in CVD risk with the Mediterranean diet (Trichopoulou, 2005). Both Mediterranean 
groups showed significant improvements in blood pressure, blood glucose, cholesterol: 
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HDL ratio, and HDL levels, compared with the low-fat group. The Mediterranean diet 
with nuts also showed decreases in total cholesterol and triglycerides (McMillan-Price, 
Petocez, & Atkinson, 2006).  
The TLC diet and Mediterranean-type diets have been recommended for the 
treatment of metabolic syndrome as they seem to be effective in promoting long-term 
adherence. Since patients with metabolic syndrome may differ in their clinical picture, 
their responses to different dietary approaches, treatments are best individualized 
(Melanson, 2008). While some of the factors that predict heart disease risk (including 
age, gender, and family history) are not variable, progression of most types of heart 
diseases can be modified by lifestyle choices. 
Diet counseling. A Cochrane Review was revised in 2007 on the effects of dietary 
advice given by a dietitian compared with another health professional or the use of self-
help resources in reducing blood cholesterol in adults (Thompson et al., 2003). This study 
assessed the effects of providing dietary advice to healthy adults in order to produce 
improvement in their diets over a sustained period of time and examined whether dietary 
improvement would reduce the risk factors associated with heart disease. They studied 38 
trials in which 17,871 healthy adults were randomly assigned to receive dietary advice or 
no dietary advice.  
The dietary improvements recommended to the people in the intervention groups 
centered largely on the reduction of salt and fat intake and an increase in the intake of 
fruit, vegetables, and fiber (Thompson et al., 2003).  Advice was delivered in a variety of 
ways, including one-to-one contact, group sessions, and written materials. There were 
variations in intensity of intervention, ranging from one contact per study participant to 
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50 hours of counseling over 4 years. The duration of the trials ranged from 3 months to 4 
years, with a median follow-up period of 10 months. Participants receiving advice from 
dietitians experienced a greater reduction in blood cholesterol than those receiving advice 
only from doctors (-0.25 mmol/L [95% CI, -0.37, -0.12 mmol/L]). There was no 
statistically significant difference in change in blood cholesterol between dietitians and 
self-help resources (-0.10 mmol/L [95% CI, -0.22, 0.03 mmol/L]). No statistically 
significant differences were detected for secondary outcome measures between any of the 
comparisons with the exception of dietitian versus nurse for HDL-C, where the dietitian 
group showed a greater reduction (-0.06 mmol/L [95% CI, -0.11, -0.01]) and dietitian 
versus counselor for body weight, where the dietitian group showed a greater reduction (-
5.80 kg [95% CI, -8.91, -2.69 kg]) (see Figure 2.1). 
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There were some problems with this dietary review. First, according to the 
inclusion/exclusion criteria, studies were not examined for medical nutritional therapy 
versus other types of counseling. Medical nutritional counseling by a dietician includes 
an individualized approach with at least one follow-up visit. Second, studies of 
nutritionists were included, addressing the effectiveness of counseling given by a 
registered dietitian who has received education via an American Dietetic Association 
(ADA) accredited program and internship. Studies included in the Cochrane Review were 
of a variety of individuals, including those with normal cholesterol values and not 
specifically metabolic syndrome. Finally, the analysis was based on a limited number of 
studies, some of which were of dubious quality, and some that may not have met the 
inclusion criteria on a drop-out of approximately 20%.  
Gami et al (2007) found 37 eligible studies that included 43 cohorts (from 1971 
to 1997) and 172,573 individuals.  Meta-analysis showed metabolic syndrome had a 
relative risk (RR) of cardiovascular events and death of 1.78 (95% confidence interval 
[CI] 1.58 to 2.00). The association was stronger in women (RR 2.63 vs. 1.98, p = 
0.09) and in studies using factor analysis or the World Health Organization definition 
(RR 2.68 and 2.06 vs. 1.67 for National Cholesterol Education Program definition and 
1.35 for other definitions; p = 0.005).   Cardiovascular events were about 33% higher for 
women than men, according to seven studies that provided separate risk analyses for both 
sexes. As part of the study, investigators did a separate meta-analysis of studies that 
simultaneously adjusted for metabolic syndrome and its components. The relative risk 
was 1.54 (95% CI 1.32-1.79).  Women should be aware that they are at higher risk. “We 
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generally think of men having a higher risk of CVD, but with the metabolic syndrome, it 
appears women have a higher risk relative to men,” Gami et al. stated (2007, p. 412).  
Dansinger (2007) in a meta analysis of 46 trials of dietary counseling revealed a 
maximum net treatment effect of -1.9 (95% CI, -2.3 to -1.5) BMI units (approximately -
6%) at 12 months. These studies were identified through a previously published 
systematic review: MEDLINE and the Cochrane Central Register of Controlled Trials 
from 1997 through July 2006.  The authors included only weight loss studies with a 
dietary component. Different analyses suggested that calorie recommendations, 
frequency of support meetings, inclusion of exercise, and diabetes may be independent 
predictors of weight change. Studies were generally of moderate to poor methodological 
quality. They had high rates of missing data and failed to explain these losses.  
Franz (2008) identified randomized controlled trials (RCTs) that evaluated weight 
loss interventions in overweight or obese adults and had >1 year follow-up. Eighty RCTs 
(n=26 455, mean age 23–69 y, 0–100% men) met the selection criteria. At baseline, mean 
weight was 77–131 kg and mean body mass index was 29–43 kg/m2. The interventions 
included advice only (28 RCTs), exercise (6 RCTs), diet (51 RCTs), diet plus exercise 
(17 RCTs), meal replacements (7 RCTs), very-low-energy diet (11 RCTs), orlistat (13 
RCTs), and ibutramine (7 RCTs). No RCT on bariatric surgery was found. Study duration 
ranged from 12 to 60 months. Overall patient follow-up was 69%.  For most 
interventions, maximum weight loss occurred early in the study (pooled mean weight loss 
at 6 mo was 0.7 kg for advice only, 2.4 kg for exercise, 4.9 kg for diet, 7.9 kg for diet 
plus exercise, 8.2 kg for sibutramine, 8.3 kg for orlistat, 8.6 kg for meal replacements, 
and 18 kg for very-low-energy diet), with some re-gain over time. Except for advice only, 
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mean weight did not completely return to baseline level by study end. Meta-analysis 
showed that reduced-energy diets, with or without exercise, resulted in more weight loss 
than advice alone.  The results of the comprehensive review by Franz et al. (2007) 
support guidelines for weight loss:  a multifaceted approach of diet, exercise, and 
behavioral therapy, with the addition of medication if the initial approach is not effective 
after 6 months. As expected from clinical experience, early weight loss was followed by a 
plateau. Weight re-gain occurred with all interventions, including after discontinuing the 
weight loss medications. It is important to note that the long-term safety of these 
medications is unknown. On average, participants in diet and exercise, medication, or 
meal replacement interventions maintained a 4–8% weight loss at >1 year, approximating 
the 5–10% weight loss advised for health benefits. 
Reviews of the significant meta-analyses identified in this project are listed in 
Table 2.4. While all of these findings are applicable to clinical practice, clinicians can use 
this evidence to motivate patients when counseling them to reduce risk factors associated 
with metabolic syndrome.  Medications and meal replacements, although more effective 
than diet alone, are not recommended or accessible for all patients, especially in the 
uninsured population.  They also must be accompanied by diet, exercise, and behavioral 
therapy. The evidence demonstrating the effectiveness of specific interventions in 
preventing cardiovascular disease in this population with metabolic syndrome is limited. 
This project examines the evidence for the use of nutritional interventions in addressing 
the modifiable risk factors. 
 
   
Table 2.4  Meta-Analysis Evaluation 
Question Cochrane 
Review 
2007 
Gami et 
al.,  
2007 
Dansinger 
et al., 
2007 
Franz et 
al. 
2007 
Will the answer if true, have a direct bearing on the health of patients? Yes Yes Yes Yes 
Is the outcome or topic something that patients/clients/population groups would care about? Yes Yes Yes Yes 
Is the problem addressed in the review one that is relevant to practice? Yes Yes Yes Yes 
Will the information, if true, require a change in practice? Yes Yes Yes Yes 
Was the question for the review clearly focused and appropriate? Yes Yes Yes Yes 
Was the search strategy used to locate relevant studies comprehensive? Were the databases 
searched and the search terms used described? 
Yes Yes Yes Yes 
Were explicit methods used to select studies to include in the review? Were inclusion/exclusion 
criteria specified and appropriate? Were selection methods unbiased? 
Yes Yes Yes Yes 
Was there an appraisal of the quality and validity of studies included in the review? Were appraisal 
methods specified, appropriate, and reproducible? 
Yes Yes Yes Yes 
Were specific treatments/interventions/exposures described? Were treatments similar enough to be 
combined? 
No Yes No No 
Was the outcome of interest clearly indicated? Were other potential harms and benefits considered? Yes Yes Yes Yes 
Were processes for data abstraction, synthesis, and analysis described? Were they applied 
consistently across studies and groups? Was there appropriate use of qualitative and/or quantitative 
synthesis? Was variation in findings among studies analyzed? Were heterogeneity issued 
considered? If data from studies were aggregated for meta-analysis, was the procedure described? 
??? Yes No No 
Are the results clearly presented in narrative and/or quantitative terms? If summary statistics are 
used, are levels of significance and/or confidence intervals included? 
Yes Yes Yes Yes 
Are conclusions supported by results with biases and limitations taken into consideration? Are 
limitations of the review identified and discussed? 
No Yes No No 
Was bias due to the review’s funding or sponsorship unlikely? Yes Yes Yes Yes 
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"The time has come to apply to diet research the same level of evidence required 
for other interventions. We believe that indications or claims made for weight loss or 
health improvement via diet—whether made by authors, the government, or 
associations—must be supported by 3 types of evidence: proof that the diet provides 
essential nutrients in actual patients, efficacy studies, and randomized, controlled trials 
with clinical events as end points....Until then, the public will continue to be subject to 
speculation and potentially hazardous extrapolation from putative biological surrogates to 
clinical outcomes" (Yancy, Westman, French, & Califf, 2003, p. 14). 
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Chapter Three: Methodology 
This chapter includes a description of the design, setting and sample for the 
project. This is followed by a discussion of the methods and procedures for the study, 
including the protection of human subjects.  
Study Design 
This project was the implementation of an evidence-based practice change 
incorporating an intensive dietary program for patients with metabolic syndrome and an 
evaluation of the effect of that change on lipoproteins, glucose, blood pressure, weight, 
and waist circumference. This study was a one-group before-and-after design, with 
baseline data obtained on patients prior to the practice change. The study ran for six 
months. 
Setting 
The setting for the study was a medical practice in a large city in the southeastern 
U.S. The practice had both physicians and nurse practitioners providing primary care 
services. The clinic serves uninsured residents of the county who have an income level of 
not more than 150% of federal poverty criteria. The clinic patient demographics were as 
follows: Caucasian (44%), African American (30%), Asian American (11%), 
Latino/Hispanic (9%), and 5% classified as other. The demographics for the county 
include:  Caucasian (64.4%), African American (29.8%), Latino/Hispanic (6.3%) and 
1.8% classified as other (VIM-JAX, 2008 Data).  There were approximately 5,000 
patients in this practice, approximately 22% of whom have metabolic syndrome.  
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Sample 
This project was offered to all new patients of the practice who met the criteria for 
metabolic syndrome. The subjects were eligible for participation in this study if they met 
three or more of the five NCEP-ATP III criteria for identifying metabolic syndrome 
(Grundy et al., 2005): 
1. Waist circumference > 35 in. for women and > 40 in. for men. 
2. Blood pressure with either diastolic > 134 or systolic > 84 mm HG. 
3. Fasting triglycerides > 150 mg/dL. 
4. HDL-C < 50 mg/dL for women and < 40 mg/dL for men. 
5. Fasting blood glucose ≥ 100 mg/dL or the presence of type 2 diabetes. 
Patients who already had type 2 diabetes or hypertension were able to be included 
in this study. Exclusion: Participants who were younger than 21 years of age were 
excluded from this project. If a person had a history of medical noncompliance 
documented in the medical record, they were excluded.  
Methods 
Data collection for this study took place over a period of six months, beginning in 
early July 2008 and ending in December 2008. Subjects were identified by the clinic 
medical director and clinical director as potential participants. The subjects were new to 
the practice with the diagnosis of metabolic syndrome based on the ATP III guidelines. 
Once the diagnosis was verified by chart review, the researcher spoke to the participants 
to thoroughly explain the research and they were told they could terminate the interview 
at any time if they so desired. After the explanation was completed, the participant was 
given the opportunity to ask questions. Once written consent to participate was obtained, 
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participants were counseled by the researcher or the clinic director regarding the diet 
program. The patients were told it would take approximately three one-hour sessions with 
the graduate dietary intern over a six-month period.  
Data Collection 
 Blood pressure, weight, waist circumference, and exercise participation were 
measured on entry into the study. A dietary assessment was performed using a 24 hour 
dietary recall. Fasting blood levels were determined for lipoproteins and blood glucose. 
These parameters were assessed again at 3 months and 6 months. 
Blood pressure. Blood pressure was measured by the graduate dietary intern who 
had been individually trained following the guidelines published by the American Heart 
Association (Pickering et al., 2005). Blood pressure was recorded in the sitting position 
using the right arm to the nearest 2 mmHg with a sphygmomanometer. Two readings 
were taken 5 min apart, and the mean of the two was taken as the blood pressure. 
Weight. Weight was evaluated in pounds using the same DetectoTM office scale. 
Weight was measured by the graduate dietary intern with the patient fully dressed and 
without shoes. Although the standard is that calibration of the scale within the last year 
resulted in scales with significantly more precise readings (p<0.001) (Stein, Haddock, 
Poston, Catanase, & Spertus, 2005), for the purposes of this study, monthly calibration 
was done  
Waist circumference. Waist girth was measured as the narrowest circumference 
between the bottom of the rib cage and the iliac crest by using an unstretched tape 
measure (Katzmarzyk et al, 2006). Waist circumference was measured by the graduate 
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dietary intern using the same tape measure for each patient. Waist circumference was 
measured at the level of the umbilicus with clothing from around the waist removed.  
Lipoproteins and fasting glucose. Blood samples from all individuals were 
obtained after a 12-hour fasting period. Samples were analyzed by Consolidated 
Laboratories. Consolidated Laboratory Services is a comprehensive laboratory that 
services medical facilities throughout northeast Florida and southeast Georgia. The 
laboratory is subject to stringent internal and external quality control programs. They 
have a planned systematic process for monitoring, evaluating, and continually improving 
the quality of laboratory services.  
Intervention 
Participants continued to receive the usual primary care at the clinic. Additionally 
they received dietary counseling strategies designed to prevent Type 2 diabetes and 
cardiovascular disease by the achievement and maintenance of normal body weight and 
reduction of abdominal obesity, blood lipid values, fasting blood glucose levels, and 
blood pressure. Each participant was counseled by a graduate nutrition intern from the 
University of North Florida regarding the Mediterranean and TLC diets. The best dietary 
pattern contains elements from each of the diets described here: an emphasis on whole-
grain carbohydrates, unsaturated fats, fruits, vegetables, legumes, and lean protein, with 
reductions in saturated and trans fats and refined carbohydrates. Participants were 
counseled and assisted to choose foods from the two diets that would fit in with their 
personal likes and lifestyles because the most important process is finding a diet the 
person can adopt for the long term in combination with regular exercise (Zivkovic, 
German, & Sanyal, 2007).  
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Participants took part in three individualized nutrition counseling sessions 
scheduled at 4-6 weeks intervals (see Appendix C).  The initial session was used to obtain 
a 24-hour diet recall, occupation, living situation and current life situation. The session 
topic, “10 Steps to a Healthy Lifestyle,” reviewed the importance of fiber, reading food 
labels, importance of exercise, pedometer use, proper portion sizes, low-fat food choices 
and how to complete a food journal.  
The second session included information on eating out, healthy snacking, and 
omega-3 fatty acids. Examples of healthy entrees and snacks were given. Subjects were 
given samples of whole grain cereal.  
Protection of Human Subjects  
Session three focused on Internet resources. The websites provided were for 
healthy recipes, motivation, exercise, healthy living tips, and nutrition databases. To 
encourage intake of water and calorie-free fluids subjects were given a water bottle.  
Each subject was given lab order form and instructed to get the blood drawn (fasting) at 
the beginning of the week of their next appointment. During the third session a final 24-
hour food recall was obtained. Results of new lab work were discussed and comparisons 
were made from the initial visit.  
Permission to conduct this study was obtained from the investigator’s project 
committee, the Institutional Review Board for The University of North Florida, and the 
executive board of the clinic. Subjects were provided essential information for informed 
consent and signed a consent form. The benefit-risk ratio was assessed for this study, 
indicating important benefits and minimal risk.  
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Chapter Four: Results 
This chapter describes the study population using mean scores and frequency of 
the variables.  Analyses were executed using SPSS statistical software (version 16.0, 
2007, Chicago, IL) with statistical significance determined at p≤.05. Data were analyzed 
using descriptive statistics and non-parametric t-tests to determine changes in metabolic 
syndrome indicators from pretest to posttest.  Pearson correlation coefficients were 
calculated to quantify the associations among variables. 
Demographic Data 
Twenty-three individuals signed consent to participate in the study, but only 19 
completed the study. There were no significant differences in either demographic or 
study variables at the initial data collection point between those who completed the study 
and those who did not. Data analysis is based on the 19 who completed the study.  
Subjects were between 29 and 58 years-of-age (M=45.21, SD=8.68); predominately 
female (n=16, 84.21%); and predominately Caucasian (n=13, 68.42%) with 4 (21.05%) 
African-Americans and 2 (10.53%) Hispanics. Fifteen (78.95%) of the participants 
smoked cigarettes. Demographic variables of the sample were not significantly different 
from the demographics of patients in the clinic.  Table 4.1 presents the baseline measures 
related to body measurements.  
Dietary Adherence 
Examination of the 24-hour diet recalls at baseline and six months revealed no 
significant difference in any of the dietary variables (see Table 4.2) 
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Table 4.1  
Baseline Measures of Sample (n = 19) 
Participants 
 Mean SD 
Waist Circumference  46.43 +6.95 
Body Weight 252.22 +58.07 
BMI 40.9 +9.76 
 
Table 4.2  
24- hour Diet Recall (n=13) 
Food Group 
(recommended # of 
servings) 
Average # 
Servings at 
Baseline 
Average # Servings 
After 6 Months 
Change 
Bread, Cereal, Rice, and 
Pasta (6-11 servings) 
4.0 
 
3.31 -0.69 
Vegetables (3-5 servings) 1.54 1.31 -0.23 
Fruits (2-4 servings) 1.46 1.46 0.0 
Milk, Yogurt, and Cheese  
(2-3 servings) 
1.85 2.31 +0.46 
Meat, Poultry, Fish, Dry 
Beans, Eggs, and Nuts  
(2-3 servings) 
3.62 3.23 -0.39 
Fats, Oils, and Sweets  
(use sparingly) 
2.85 2.69 -0.16 
 
The data from the participants who completed the 24 hour diet recall was only 
thirteen of the nineteen patients in the study.   We relied on self-reported dietary intake, 
but we validated the dietary assessment individually to minimize the amount of missing 
data. Finally, one might argue that the unique nature of the clinic in this study makes it 
difficult to generalize the results to clinic setting. However, we believe that similar 
strategies to maintain adherence could be applied elsewhere. 
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Comparison of Metabolic Syndrome Indicators Before and After Dietary Intervention 
Because not all participants returned to the clinic for data collection at the 3-
month session, only baseline and 6-month data were consistently available for 19 
participants. Changes were measured and calculated by subtracting the baseline value 
from the 6-month value. The mean change in metabolic syndrome indicators for each 
variable indicates that the study group had significantly improved systolic and diastolic 
blood pressure, total cholesterol, fasting glucose, triglycerides, HDL and LDL levels 
compared to the group from baseline to post-intervention as illustrated in Table 4.3.   
 
Table 4.3 
 
Study Group Mean Diagnostic Indicators from Baseline to Post-Intervention (n=19) 
 
Data (Mean) 
Initial 6 Months  Change 
Weight (pounds)  252.2 261.78 9.58 
Body mass index (kg/m2) 40.9 42.37 1.47 
Waist Circumference (in) 46.43 46.7 0.27 
Fasting Glucose (mmol/L) 98.87 95.92 -5.08 
Systolic blood pressure (mm Hg) 136.74 127.11 -13.89 
Diastolic blood pressure (mm Hg) 93.22 81.67 -12.11 
Triglycerides* (mmol/L) 147.57 129.47 -5.07 
High-density lipoprotein(mmol/L) 39.30 43.67 3.47 
Low-density lipoprotein 
(mmol/L) 121.00 113.47 
-6.13 
 
Pearson correlation analyses revealed no significant association between the 
demographic variables of age, race, gender, and smoking with any of the outcome 
variables themselves, or with the post-intervention change.  Participants varied in the 
number of dietary counseling sessions they attended. While 14 of the 19 participants 
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(73.68%) had one or more visits, only 5 (26.32%) had more than three total visits. There 
was no discernable pattern of association between the dose of the dietary intervention 
(that is, the number of visits) and metabolic syndrome indicators.  
Although the intent at the outset of the study was to hold medications constant, in 
fact, three individuals (15.79%) had cholesterol-lowering medication changes and two 
individuals (10.53%) had antihypertensive medication changes during the course of the 
study. There was no significant association between the medication changes and the 
metabolic syndrome indicators. 
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Chapter Five: Conclusion 
This chapter provides a discussion of the study findings relevant to the dietary 
intervention and lessons learned in the process. Implications for evidence-based 
practice and future research are also presented.  
Discussion 
The aim of this project was to determine whether dietary changes related to 
nutrition counseling can improve the outcomes of patients with metabolic syndrome at 
the Volunteer in Medicine Jacksonville Clinic (VIM-JAX) in Jacksonville, FL. 
Additionally, age, gender, and baseline laboratory studies as predictors of weight loss 
were explored.  Diet has been shown to be a major contributor to metabolic syndrome in 
susceptible individuals (Grundy et al., 2005).  Among adults, the prevalence of obesity 
and overweight has increased rapidly over the last 15 years to 65% and parallels the 
increase in diabetes.   The prevalence of metabolic syndrome increases with age and 
varies by ethnicity, with Hispanics having the highest age-adjusted prevalence compared 
with other ethnic groups. Hispanics currently represent over 14% of the total U.S. 
population and have a projected growth to 25% of the total population by 2050 (Noel, S., 
Newby, P., Odrovas, J., & Tucker, K., 2009).   Even though only 9% of the population at 
VIM-JAX is Hispanic, 21% of the participants were in this group.  
Results of the study showed marked improvement in all of the variables for 
hypertension and dyslipidemia (blood pressure, FBS, HDL, LDL and triglycerides).  On 
the other hand, both BMI and weight increased overall in this study group.  Multiple 
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attempts to identify correlation between these variables and dietary intervention were 
unsuccessful.  Also, most of the patients (94%) were either on a lipid lowering agent 
and/or antihypertensive throughout the study which may have affected the outcomes.  
This study failed to support the hypothesis that TLC dietary intervention will improve 
metabolic syndrome parameters in an uninsured population.  Most of the individuals 
affected by metabolic syndrome are overweight, therefore dietary treatment should be 
primarily focused on weight reduction.  Therefore a diet to treat individuals with 
metabolic syndrome will have some general characteristics, but will have specific 
properties to take into account the abnormalities present in that individual patient (i.e. 
hypertension and dyslipidemia).  “In the absence of clear scientific evidence, individuals 
with metabolic syndrome will continue to be treated with multiple drug prescriptions that 
mitigate the symptoms, but are inadequate to treat the disease” (Riccaradi & Reveilles, 
2000, p. S147). 
Limitations 
Lack of uniform definition.  There were many limitations to this study that should 
be noted.  First, the lack of a uniform definition of the Metabolic Syndrome was a 
limitation for this study. Although the Metabolic Syndrome is a well recognized clinical 
phenomenon, there is no accepted definition, and the physiological changes in childhood 
make the definition particularly difficult to classify. Johnson and Weinstock (2006) 
have shown the NCEP ATP III criteria to have definite flaws. “First, the 5 criteria and 
the cutoffs appear to be arbitrary and not evidence based. Second, the risk factor values 
are continuous and must be considered as such, not just as present or absent. The fact that 
CVD risk increases with increasing blood glucose levels, systolic blood pressure, and 
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LDL cholesterol values has been well documented. Third, important risk factors such as 
LDL cholesterol, cigarette smoking, family history, and age are not included, limiting the 
usefulness of the metabolic syndrome in predicting CVD risk” (p. 1616).  The metabolic 
syndrome has been defined in several ways and thus cannot be considered a precise 
diagnosis.  
Recently (2009), five major scientific organizations – the International Diabetes 
Federation (IDF), the (NHLBI), the AHA, the World Heart Federation (WHF), the 
International Atherosclerosis Society (IAS), and the International Association of the 
Study of Obesity (IASO) – have just released a joint interim statement that represents a 
giant leap toward a unified definition of the metabolic syndrome. Individuals who meet at 
least 3 of 5 clinical criteria will be diagnosed as having the condition; presence of none of 
these criteria is mandatory. Specific cut points are defined for all criteria, except elevated 
waist circumference, which must rely on population and country-specific definitions 
(Alberti et al., 2009).  
Weight loss limitations.  The weight loss of the subjects may not reflect fat mass 
loss. Obesity was measured by BMI and weight. This measure was used because of its 
simplicity, economical and ease of use for the clinician, however, true fat mass was not 
assessed. Weight loss generally involves the loss of both fat and lean mass and it is 
anticipated that fat mass loss contributes to improvements in Metabolic Syndrome 
markers. 
Multiple providers. Second, study participants were seen by different graduate 
dietary interns who rotated throughout the semester. Based on scheduling conflicts, the 
study participant would not see the same intern for follow-up appointments.   In addition, 
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VIM-JAX uses multiple primary care providers who followed these patients.   Rapport 
with the patient may be better with consistent providers.  Beutow (2003) cautioned 
“provider continuity will not happen if there is a lack of consistency in who attends with 
or for the patient during successive visits” (p. 509).  He also described how continuity of 
care can be weakened because the clinician may be hindered from providing a “sustained 
partnership” and having an ongoing sense of responsibility to the patient. 
Use of graduate nutrition students. Because graduate nutrition practitioners are 
educated in a wide range of practice settings, it is difficult to differentiate the varying 
levels of expertise.  There may be a lack of systematic instruction, counseling and 
coaching system caused by the use of multiple interns at VIM-Jax that impacted on the 
ability to promote effective diet change.  There is a need for more consistent training of 
the graduate nutrition interns along with the primary care providers for use of specific 
and consistent messaging via counseling or motivational interviewing and coaching.   
Lack of computer support.  Originally, the study was designed to use a dietary 
analysis computer program. The Self-Efficacy for Healthy Eating Scale (Baughman et al., 
2003) measures healthy eating self-efficacy. The instrument consists of a 20-item likert 
scale with a reliability α coefficient of 0.95 and was designed to measure participant 
ability to eat a healthy diet including eating more fruits and vegetables, eating less dietary 
fat, and eating smaller portions.  Food records of weekly intake were to be  analyzed 
using the Food Processor ™ computer program to provide mean dietary energy intake, 
daily grams of fiber, percentage of calories from fat, saturated fat, protein, and 
carbohydrates; and daily servings of fruits and vegetables. The Food Processor instantly 
compares patient dietary intake against recommended nutrient standards, analyzing as 
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many as 164 nutritional components. It includes a database of over 32,000 foods, recipes 
and exercises and users can add an unlimited number of foods and modify existing foods 
(ESHA research).  Because of outdated and limited computer support at VIM-JAX, this 
program was unavailable for use.   
Scheduling conflicts.  Finally, individuals who were recruited for the current study 
had to attend the nutrition appointments within a specified time frame. Therefore, the 
sample was limited to those who made and attended the appointments at VIM-JAX.  
Because the study used UNF graduate nutrition interns, the students’ schedule was an 
obstacle to providing choices in appointment times and dates for the study participants.   
All of the nutrition classes were only offered on Fridays when classes were in session.  
National data suggests that 12 million appointments in the primary care setting are not 
attended each year, approximately 6.5% of the appointments made (Martin, Perfect, & 
Mantle, 2005). This “no show” rate is likely to be higher in a primary care setting serving 
predominantly indigent patients who have more barriers to attending appointments (i.e., 
transportation, work schedule, daycare).  
Conclusion 
Those with metabolic syndrome have significantly higher risks for developing 
diabetes and cardiovascular disease. Public health experts estimate that billions of dollars 
in medical costs are spent managing patients with metabolic syndrome each year in the 
United States. Morbidity and mortality stemming from obesity and metabolic syndrome 
has reached epidemic proportions.  Aggressive treatment of metabolic syndrome is 
critical for the health of the world’s population. More research is necessary to identify the 
components that are most effective for weight loss especially in the primary care setting. 
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Specifically, evidence based studies are needed with this population comparing 
medical and pharmacotherapy versus more general dietary/exercise interventions.  The 
issue of the confounding variables related to medication vs. diet and different outcomes 
based on adherence to one or the other and subsequent outcomes needs more research.  
Twenty eight percent of the participants in the study were either on an antihypertensive or 
lipid lowering agent or both.   
The optimal management of patients at high risk for cardiovascular disease 
requires both assessment and treatment of the modifiable cardiometabolic risk factors 
established by evidence-based guidelines.  “The ultimate utility of even considering 
metabolic syndrome may simply be to provide patients and clinicians a framework in 
which to discuss the importance of multiple risk factors and interventions, especially if 
the patient has no symptoms and therefore is likely to be unmotivated and more likely to 
choose pharmacotherapy when ill than lifestyle changes before irreversible illness 
occurs” (Stolar, 2007, p. 207).   
Lifestyle changes are the most important element in helping patients stop the 
progression of metabolic syndrome to cardiovascular disease.  These are often the most 
difficult patients for health care providers to manage.  "Motivational interviewing" is 
another useful strategy that can aid the provider when resistance is met or the challenge 
to change seems burdensome.  Motivational interviewing is a 3-step, therapeutic 
approach that can assist providers in encouraging behavior change in their patients with 
metabolic syndrome (West, DiLillo, Bursac, Gore, & Greene, 2007).   Numerous studies 
have shown that trust between a health care provider and a patient is one of the most 
important elements contributing to a patient’s success (Beutow, 2003).  Yet patients find 
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it difficult to undertake the recommendations we ask of them.  If we could identify 
metabolic syndrome patients who are at risk of developing diabetes or cardiovascular 
disease, we might be able to intervene earlier.  By gaining skills to help motivate, 
encourage, and support patients in successfully implementing lifestyle changes to 
improve their health status, clinicians can enhance their patients’ wellness and begin 
reducing the burden of cardiovascular disease in the U.S.   
“The time has come to apply to diet research the same level of evidence required 
for other interventions. We believe that indications or claims made for weight loss or 
health improvement via diet—whether made by authors, the government, or 
associations—must be supported by 3 types of evidence: proof that the diet provides 
essential nutrients in actual patients, efficacy studies, and randomized, controlled trials 
with clinical events as end points” (Yancy, et al., 2003, p. 14). 
 As clinicians, “if we could identify patient subgroups truly at risk of developing 
diabetes or cardiovascular disease, we might be able to intervene earlier and more cost-
effectively, rather than screening and treating the general population” (Stolar, 2007, p. 
206).  The ultimate reason to identify metabolic syndrome may simply be to provide 
patients and clinicians a framework in which to discuss the importance of multiple risk 
factors and interventions.  This is especially important if the patient has no symptoms and 
therefore is likely to be unmotivated and more likely to choose pharmacotherapy than 
lifestyle changes.  
 
   
 
Appendix A: Critical Analysis Table: Review of the Evidence 
Author 
(Dates) 
Title  Type N Comments 
Brunner et al. 
(2007) 
Dietary advice  
 
Cochrane Review 17,871 
subjects 
Dietary advice appears to be effective in bringing about 
modest beneficial changes in diet and cardiovascular risk 
factors over approximately 10 months but longer-term effects 
are not known. 
Gami et al. 
(2007) 
Metabolic 
syndrome  
Meta-analysis and 
systematic review of 
metabolic syndrome 
and incidence of 
cardiovascular events 
37 
studies, 
172,573 
subjects 
Evidence suggested metabolic syndrome increases risk of 
cardiovascular events. 
Dansinger et 
al. (2007) 
Meta-analysis: The 
effects of dietary 
counseling  
Meta-analysis of the 
effects of dietary 
counseling compared 
with usual care in 
adults 
46 
clinical 
trials,  
11, 853 
subjects  
Compared with usual care, dietary counseling interventions 
produce modest weight losses that diminish over time.  
Franz et al. 
(2007)  
Weight-loss 
outcomes: A 
systematic review 
and meta-analysis  
 
Systematic review 
to determine types of 
weight-loss 
interventions 
that contribute to 
successful outcomes 
and to define expected 
weight-loss outcomes 
from the interventions 
 
80 RCT 
studies, 
26,455 
subjects 
Reduced-energy diets, with or without exercise, promote 
weight loss more than advice alone. Meal replacement and 
weight-management drugs promote weight loss more than diet 
alone. Regardless of intervention type, most weight loss 
occurs in the first six months, with some weight re-gain 
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Author 
(Dates) 
Title  Type N Comments 
Nordmann et 
al. (2006) 
Effects of low-
carbohydrate vs. 
low-fat diets on 
weight loss  
Meta-analysis  
comparing the effects 
of low 
carbohydrate 
diets without 
restriction of energy 
intake vs. low-fat diets 
in individuals with a 
BMI of at least 25 
5 RCT 
studies, 
447 
subjects 
Low-carbohydrate, non-energy-restricted 
diets appear to be at least as effective as low-fat, energy 
restricted diets in inducing weight loss for up to one year 
Galassi et al. 
(2006) 
Metabolic 
syndrome and risk 
of cardiovascular 
disease: A meta-
analysis 
Meta-analysis 
examining the 
association between 
the metabolic 
syndrome and risk of 
cardiovascular disease 
21 
Prospect
ive 
cohort 
studies, 
78,769 
subjects 
This meta-analysis indicated that individuals with the 
metabolic syndrome have a 61% increased risk of 
cardiovascular disease compared to individuals without the 
metabolic syndrome 
Yamaoka & 
Tango (2005) 
Efficacy of 
lifestyle education  
Meta-analysis 
evaluating the efficacy 
of lifestyle education 
for preventing type 2 
diabetes in individuals 
at high risk by meta-
analysis of RCTs 
 
 
9 RCT 
studies, 
10,461 
subjects 
Lifestyle education interventions of the studies varied widely. 
This meta-analysis provided evidence of a relationship 
between lifestyle education in high risk subjects and the 
prevention of type 2 diabetes 
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Author 
(Dates) 
Title  Type N Comments 
AHRQ (2005) Screening for 
metabolic 
syndrome  
Guideline using a 
review of published 
meta-analyses, 
systematic reviews, 
and systematic reviews 
with evidence tables. 
 
N/A The recommendations were based primarily on sources such 
as national guidelines and consensus statements written on 
hyperlipidemia, hypertension, and diabetes mellitus by the 
National Cholesterol Education Program Expert Panel, the 
Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure, and Workgroup of the 
American Diabetes Association. Guidelines and statements 
were synthesized to make them applicable to the screening 
and treatment of metabolic syndrome 
Groeneveld et 
al. (2008) Evaluating the 
cost- effectiveness 
of a lifestyle 
intervention  
RCT 692 
subjects 
By improving lifestyle, CVD risk may be lowered, yielding 
benefits for both employee and employer. By improving 
lifestyle, CVD risk may be lowered, yielding benefits for both 
employee and employer. If proven effective, this lifestyle 
intervention will be implemented on a larger scale within the 
Occupational Health Services in construction industry 
Ilanne-Parikka 
et al. (2008) Effect of lifestyle 
intervention on the 
occurrence of 
metabolic 
syndrome  
RCT 522 
subjects 
There is a significant reduction in the prevalence of metabolic 
syndrome in the intervention group compared with the control 
group, suggesting that lifestyle intervention may also reduce 
risk of cardiovascular disease 
Bo et al. 
(2007)  
Effectiveness of a 
lifestyle 
intervention on 
metabolic 
syndrome 
RCT 375 
subjects 
A lifestyle intervention based on general recommendations 
was effective in reducing multiple metabolic abnormalities 
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Author 
(Dates) 
Title  Type N Comments 
Orchard et al. 
(2005) 
The effect of 
metformin and 
intensive lifestyle 
intervention  
 
RCT 1,711 
subjects 
Metabolic syndrome affected approximately 50% of the 
participants in the Diabetes Prevention Program at baseline. 
Both lifestyle intervention and metformin therapy reduced the 
development of the syndrome in the remaining participants in 
the study 
Esposito et al. 
(2004) 
Effect of a 
Mediterranean-
style diet  
RCT 180 
subjects 
A Mediterranean-style diet might be effective in reducing the 
prevalence of the metabolic syndrome and its associated 
cardiovascular risk 
 
de Lorgeril et 
al. (1999) 
Mediterranean diet, 
traditional risk 
factors 
 
RCT 605 
subjects  
There is reduced risk of CHD mortality due to Mediterranean 
diet 
Lutsey et al. 
(2008) 
Dietary intake and 
the development of 
metabolic 
syndrome 
Prospective 
multicenter cohort 
study 
9,514 
subjects 
The consumption of a Western dietary pattern, meat, and fried 
foods promotes the incidence of metabolic syndrome, whereas 
dairy consumption provides some protection 
 
Seidel et al., 
(2008) 
Translating the 
diabetes prevention 
program into an 
urban medically 
underserved 
community 
Prospective 
intervention study 
573 
subjects 
Adults in an urban medically underserved community can 
decrease their risk for type 2 diabetes and CVD through 
participation in a group lifestyle intervention, and short-term 
sustainability is feasible 
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Author 
(Dates) 
Title  Type N Comments 
Katzmarzyk et 
al. (2006)  
The importance of 
waist 
circumference in 
the definition of 
metabolic 
syndrome 
Prospective cohort 
study 
20,789 
subjects 
Waist circumference is an important component of metabolic 
syndrome; however, the IDF requirement of an elevated waist 
circumference warrants caution given that a large proportion 
of men with normal waist circumference have multiple risk 
factors and an increased risk of mortality  
Bonora et al. 
(2003) 
Carotid 
atherosclerosis and 
coronary heart 
disease in the 
metabolic 
syndrome 
Prospective 
population-based 
survey 
888 
subjects 
Subjects with the metabolic syndrome by WHO criteria had 
an increased five-year incidence and progression of carotid 
atherosclerosis 
Osei et al. 
(2008) 
Is glycosylated 
Hemoglobin A1C a 
surrogate for 
metabolic 
syndrome 
Cross sectional 219 
subjects 
Measuring random HbA1c levels in African American 
patients serves as a surrogate of metabolic syndrome 
Dilley et al. 
(2007) 
Association of 
A1C with 
cardiovascular 
disease and 
metabolic 
syndrome  
Cross sectional 1,620 
subjects 
In Asian Indians with normal glucose tolerance, A1C showed 
an association with most CVD risk factors, the metabolic 
syndrome, and CAD 
Mendoza et 
al.  
(2007) 
Dietary energy 
density is 
associated with 
obesity and the 
metabolic 
syndrome  
Cross sectional 9,688 
subjects 
Dietary energy density is an independent predictor of obesity, 
elevated fasting insulin levels, and the metabolic syndrome in 
U.S. adults 
49 
 
   
Author 
(Dates) 
Title  Type N Comments 
Panagiotakos 
et al.  
(2004) 
The impact of 
lifestyle habits on 
the prevalence of 
the metabolic 
syndrome  
Cross sectional 3,042 
subjects 
Decreased risk of having the metabolic syndrome due to 
Mediterranean diet 
Vaidya et al. 
(2007)  
Defining the 
metabolic 
syndrome  
Cross sectional 6,781 
subjects 
Metabolic syndrome was associated with greater insulin 
resistance and was compatible with two of three “syndrome” 
constructs tested 
Strazzullo et 
al. (2008) 
Diagnostic criteria 
for metabolic 
syndrome 
Comparative 933 
subjects  
A five-fold difference in the prevalence of MS resulted from 
the use of different diagnostic criteria 
Dallongeville 
et al. (2005) 
Household income 
is associated with 
the risk of 
metabolic 
syndrome  
Comparative  1,695 
subjects 
Limited household income, which reflects a complex 
unfavorable social and economic environment, may increase 
the risk of metabolic syndrome in a sex-specific manner 
Abbreviations: A1C = ; BMI = body mass index; CAD = ; CHD = ; CVD = cardiovascular disease; RCT = randomized controlled trials. 
 
50 
51 
 
   
Appendix B: Data Collection Shee
NCEP-ATP III Definition 
t 
Data 
Initial 3 Months 6 Months 
n    
Age (years)    
Men (%)    
Body mass index (kg/m2)    
Waist, men (cm)    
Waist, women (cm)    
Glucose (mmol/L)    
Systolic blood pressure (mm Hg)    
Diastolic blood pressure (mm Hg)    
Triglycerides* (mmol/L)    
High-density lipoprotein(mmol/L)    
Low-density lipoprotein (mmol/L)    
Smokers    
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Appendix C: Dietary Counseling Sessions 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
 
 
  
 
 
 
 
 
Survey instrument deleted, paper copy available upon request.
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Survey instrument deleted, paper copy available upon request.
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